Lilly Goes Beyond Weight Loss: $2.88B Merida Deal Targets Autoimmune Growth

‼️ Eli Lilly will acquire Merida Biosciences for up to $2.88 billion in cash to broaden its autoimmune and allergy portfolio beyond its weight-loss and diabetes franchises.

Leave a comment